TAD After Chemotherapy in Locally Advanced Breast Cancer

Recruiting now

Conditions studied: Sentinel Lymph Node, Breast Cancer, Locally Advanced

In brief

This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).

Key facts

Study ID

NCT05763641

Run by

Hospital Universitari de Bellvitge

People needed

162

Starts

2021-02-01

Expected to finish

2026-06-01

Last updated by the study team

2025-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Axillary lymph node metastasis proven by cytology
• Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
• Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
• Neoadjuvant chemotherapy

You may not qualify if…

• cN3 verified by imaging tests
• N2 due to internal mammary involvement (N2b).
• Tumors whose surrogate molecular subtype is luminal A.
• Patients undergoing neoadjuvant endocrine therapy
• Patients with local recurrences and metastatic tumors.

Where it is running

• Hospital de Bellvitge — L'Hospitalet de Llobregat, Barcelona, Spain (enrolling)
• Hospital Clínico y Provincial de Barcelona — Barcelona, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.